Galmed Pharmaceuticals Ltd.
GLMD
$1.07
$0.1111.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.00% | 66.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.66% | 66.85% | |||
| Operating Income | 0.66% | -66.85% | |||
| Income Before Tax | 24.17% | -126.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.17% | -126.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.17% | -126.00% | |||
| EBIT | 0.66% | -66.85% | |||
| EBITDA | 0.67% | -67.96% | |||
| EPS Basic | 45.17% | -1.87% | |||
| Normalized Basic EPS | 30.51% | 19.60% | |||
| EPS Diluted | 45.17% | -1.87% | |||
| Normalized Diluted EPS | 30.51% | 19.60% | |||
| Average Basic Shares Outstanding | 38.30% | 121.85% | |||
| Average Diluted Shares Outstanding | 38.30% | 121.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||